CUDC-907 is a dual inhibitor targeting both histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) pathways, making it a promising agent in cancer therapy. It is primarily investigated for its antitumor activity in various hematologic and solid malignancies. By simultaneously blocking HDAC and PI3K, CUDC-907 disrupts multiple signaling pathways involved in cancer cell proliferation, survival, and apoptosis resistance. It has shown potent activity in preclinical models of lymphoma, multiple myeloma, and certain solid tumors such as lung and breast cancer. The dual inhibition enhances anti-cancer effects compared to single-pathway inhibitors and may help overcome resistance mechanisms seen with monotherapies. CUDC-907 is being evaluated in clinical trials to determine its efficacy, optimal dosing, and safety profile in patients with advanced cancers. Its ability to modulate both epigenetic regulation and key survival signaling makes it a valuable candidate in targeted oncology treatment strategies.